These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31418911)

  • 1. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine.
    Fiedler-Kelly JB; Cohen-Barak O; Morris DN; Ludwig E; Rasamoelisolo M; Shen H; Levi M
    Br J Clin Pharmacol; 2019 Dec; 85(12):2721-2733. PubMed ID: 31418911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine.
    Kielbasa W; Quinlan T
    J Clin Pharmacol; 2020 Feb; 60(2):229-239. PubMed ID: 31482569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
    Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
    JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
    Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
    Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fremanezumab for the prevention of chronic and episodic migraine.
    Lionetto L; Cipolla F; Guglielmetti M; Martelletti P
    Drugs Today (Barc); 2019 Apr; 55(4):265-276. PubMed ID: 31050694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fremanezumab for the preventive treatment of migraine.
    Silberstein SD; Cohen JM; Yeung PP
    Expert Opin Biol Ther; 2019 Aug; 19(8):763-771. PubMed ID: 31177856
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach.
    Cohen-Barak O; Radivojevic A; Jones A; Fiedler-Kelly J; Gillespie M; Brennan M; Gutman D; Rasamoelisolo M; Hallak H; Loupe P; Kessler Y; Ning X; Levi M; Ahn AH; Rabinovich-Guilatt L
    Cephalalgia; 2021 Sep; 41(10):1065-1074. PubMed ID: 34000848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
    Silberstein SD; McAllister P; Ning X; Faulhaber N; Lang N; Yeung P; Schiemann J; Aycardi E; Cohen JM; Janka L; Yang R
    Headache; 2019 Jun; 59(6):880-890. PubMed ID: 30977520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses.
    Fiedler-Kelly J; Passarell J; Ludwig E; Levi M; Cohen-Barak O
    Headache; 2020 Jul; 60(7):1376-1391. PubMed ID: 32445498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
    Friedman DI; Cohen JM
    Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
    Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
    Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
    Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
    Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
    Parikh SK; Burkett JG; Silberstein SD
    Expert Opin Drug Saf; 2020 May; 19(5):537-543. PubMed ID: 32116061
    [No Abstract]   [Full Text] [Related]  

  • 14. Fremanezumab: First Global Approval.
    Hoy SM
    Drugs; 2018 Nov; 78(17):1829-1834. PubMed ID: 30406901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fremanezumab for the Preventive Treatment of Chronic Migraine.
    Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
    N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
    MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
    J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
    Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
    J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fremanezumab for the preventive treatment of migraine in adults.
    Lionetto L; Curto M; Cisale GY; Capi M; Cipolla F; Guglielmetti M; Martelletti P
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):741-748. PubMed ID: 31220963
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
    Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
    J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.